Clinical Efficacy of Compound Biejia Ruangan Tablets Combined With Entecavir for the Treatment of Decompensated Chronic Hepatitis B-Related Cirrhosis: A Multiparameter Evaluation
Hepatitis Monthly · 19.05.2026 · 26 (1)
DOI: 10.5812/hepatmon-171154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Monthly, online erschienen am 19.05.2026. Verfasst von Lixia Yu und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic hepatitis B-related cirrhosis is a progressive liver disease that can lead to decompensation, recurrent portal hypertension-related events, impaired liver function, and poor long-term outcomes. Recompensation has recently been recognized as a clinically meaningful treatment goal in selected patients with decompensated cirrhosis. Compound Biejia Ruangan Tablets (CBRT), an antifibrotic traditional Chinese medicine formulation, may provide additional benefits when combined with antiviral therapy.
Objectives
To evaluate the therapeutic efficacy and safety of CBRT in achieving recompensation after decompensation in chronic hepatitis B-related liver cirrhosis.
Methods
Sixty individuals with chronic hepatitis B-related liver cirrhosis who experienced their first decompensation event were enrolled and randomly assigned to an observation group or a control group, with 30 patients in each group. The observation group received CBRT, four tablets per dose, three times daily, combined with one entecavir tablet nightly. The control group received one entecavir tablet in addition to standard diuretics and hepatoprotective medications. The treatment duration was 6 months in both groups. General conditions and clinical symptoms were recorded. Laboratory assessments included liver function tests, the FIB-4 index, platelet count, total protein, albumin, hepatitis B surface antigen titer, hepatitis B virus DNA, and four indices of liver fibrosis, which were measured before and after treatment. Decompensation events within 1 year and serious outcomes, including death and liver transplantation, were also recorded during follow-up.
Results
Both the observation and control groups showed decreases in hepatitis B surface antigen titer, hepatitis B virus DNA load, and total bilirubin compared with pretreatment levels. Compared with the control group, the observation group showed greater improvements in albumin, FIB-4, liver fibrosis indices, and platelet count (P < 0.05). The incidence of decompensation events was higher in the observation group than in the control group, with minimal adverse events reported in both groups.
Conclusions
As an adjunct to antiviral therapy for chronic hepatitis B-related liver cirrhosis, CBRT may help delay disease progression, reduce the risk of recurrent decompensation-related events, and improve liver function and clinical symptoms. These findings provide a useful reference for comprehensive clinical care.
Zitieren
APA
Yu, L., Ma, M., Shen, J., Zhu, Y., Chen, M., Li, M., & Zhou, Y. (2026). Clinical Efficacy of Compound Biejia Ruangan Tablets Combined With Entecavir for the Treatment of Decompensated Chronic Hepatitis B-Related Cirrhosis: A Multiparameter Evaluation. Hepatitis Monthly, 26(1). https://doi.org/10.5812/hepatmon-171154
Vancouver
Yu L, Ma M, Shen J, Zhu Y, Chen M, Li M, et al. Clinical Efficacy of Compound Biejia Ruangan Tablets Combined With Entecavir for the Treatment of Decompensated Chronic Hepatitis B-Related Cirrhosis: A Multiparameter Evaluation. Hepatitis Monthly. 2026;26(1). doi:10.5812/hepatmon-171154
BibTeX
@article{Yu2026,
author = {Yu, Lixia and Ma, Mengjie and Shen, Jiacong and Zhu, Yuwen and Chen, Mingzhuan and Li, Minghui and Zhou, Yiqing},
title = {Clinical Efficacy of Compound Biejia Ruangan Tablets Combined With Entecavir for the Treatment of Decompensated Chronic Hepatitis B-Related Cirrhosis: A Multiparameter Evaluation},
journal = {Hepatitis Monthly},
year = {2026},
volume = {26},
number = {1},
doi = {10.5812/hepatmon-171154}
}
EUVIMED